TY - JOUR AU - de Melo Rodrigues, Ana Luiza AU - Victor Gottardello Zecchin, AU - Maria Lúcia de Martino Lee, AU - Antonella Adriana Zanette, AU - Adriana Seber, AU - Raul Corrêa Ribeiro, PY - 2021/11/30 Y2 - 2024/03/28 TI - Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia - SBTMO/SOPOBE 2020 Consensus Guidelines: SBTMO/SOPOBE Guidelines: Pediatric AML JF - JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY JA - jbmtct VL - 2 IS - 4 SE - Original article DO - 10.46765/2675-374X.2021v2n4p139 UR - https://www.jbmtct.com.br/seer/index.php/jbmtct/article/view/139 SP - 139 AB - <p>Acute myeloid leukemia (AML) represents 15%–20% of acute leukemias in children, and the risk of treatment failure is based on genetic risk and response to therapy<sup>1-4</sup>. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity<sup>5</sup>. The best therapeutic results are achieved by integrating intensive chemotherapy, optimal supportive care, and hematopoietic stem cell transplant (HSCT) adapted to each patient’s risk of relapse<sup>6–9</sup>. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML to provide evidence-based guidance for the appropriate management of this disease.</p> ER -